AI Meets Academia: A New Blueprint for Drug Discovery in Israel

REHOVOT, ISRAEL and TEL AVIV, ISRAEL – July 08, 2026 – A strategic new initiative is set to reshape the pathway from academic lab to clinical reality in Israel's vibrant life sciences sector. Computational chemistry firm Evogene and Tel Aviv University's prestigious Blavatnik Center for Drug Discovery (BCDD) have joined forces, aiming to accelerate the development of novel small-molecule drugs. The collaboration, facilitated by the university's tech transfer arm, Ramot, creates a powerful framework that pairs Evogene's generative AI engine, ChemPass AI™, with BCDD's world-class experimental infrastructure.

This partnership tackles a persistent and costly bottleneck in pharmaceutical R&D: the chasm between a brilliant biological insight and a viable drug candidate. While academic institutions are fertile ground for discovering novel disease targets, they often lack the integrated resources and specialized expertise to navigate the treacherous early stages of drug discovery. By creating a unified pipeline, Evogene and BCDD are building a much-needed bridge over this 'valley of death,' potentially unlocking a new wave of therapies originating from Israeli academia.

The Engine Room: Integrating AI Design and Experimental Validation

At the heart of this collaboration is a seamlessly integrated Design-Make-Test-Analyze (DMTA) workflow, a paradigm that is rapidly becoming the gold standard in modern drug discovery. This initiative, however, is unique in how it combines two distinct centers of excellence. On one side is Evogene's ChemPass AI™, a sophisticated generative AI platform. Unlike traditional methods that screen vast libraries of existing compounds, generative AI works in reverse: it designs novel molecules from scratch, tailored to bind a specific disease target and optimized for multiple critical parameters like potency, selectivity, and drug-like properties.

This computational power is now directly fused with the BCDD's formidable experimental capabilities. The center provides the state-of-the-art infrastructure necessary to bring AI-generated designs to life and test them rigorously. This includes high-throughput screening to test thousands of compounds, medicinal chemistry labs to synthesize the most promising candidates, and a suite of in vitro and in vivo models to validate their biological activity and safety profiles.

This closed-loop system is designed for speed and efficiency. ChemPass AI™ will generate a focused set of novel molecular hypotheses. The BCDD will then synthesize and test these molecules, feeding the real-world experimental data back into the AI platform. This iterative process allows the system to learn and rapidly refine subsequent generations of compounds, dramatically shortening the timeline and reducing the immense cost typically associated with finding a promising lead candidate. It moves the process from serendipitous discovery to guided, intelligent design.

Confronting the 'Valley of Death' in Israeli Biotech

While Israel is globally recognized as a 'Startup Nation,' its life sciences sector has long grappled with the translational gap. Industry analysts note that while academic research is world-class, early-stage biotech projects often struggle to attract the necessary capital to move from a compelling paper to a preclinical asset. Venture capital, drawn to the faster returns of software and cybersecurity, has historically been more cautious about the long timelines and high-risk nature of drug development. This creates a 'valley of death' where countless promising discoveries languish for lack of funding and industrial-grade development infrastructure.

The Evogene-BCDD initiative is a direct and strategic assault on this problem. By providing an integrated, de-risked development pathway, the collaboration makes academic projects vastly more attractive for future investment and partnership. A project emerging from this framework will have more than just a biological hypothesis; it will have validated lead compounds designed by a cutting-edge AI, backed by a robust package of experimental data. This significantly lowers the barrier to entry for venture capitalists and large pharmaceutical scouts looking for their next pipeline asset.

As Ofer Haviv, President and CEO of Evogene, stated, "Israel's academic institutions generate world-class discoveries and novel therapeutic targets. However, many entrepreneurs and researchers face significant hurdles in transforming these scientific insights into viable drug development programs." He emphasized that this framework combines "advanced AI-driven computational chemistry with world-class experimental validation capabilities," creating a new conduit for innovation.

A Local Solution in a Global AI Race

The partnership arrives at a time of intense global activity in AI-driven drug discovery. Giants like Sanofi and Bayer are pouring billions into partnerships with AI firms such as Exscientia and Recursion Pharmaceuticals, while companies like Insilico Medicine are advancing their own AI-discovered candidates into human clinical trials. The race is on to leverage machine learning to make drug R&D faster, cheaper, and more successful.

Within this competitive landscape, the Evogene-BCDD model presents a compelling and differentiated approach. While many AI companies focus on partnering with established pharmaceutical giants, this initiative is fundamentally about ecosystem cultivation. Its primary goal is to capture and nurture innovation at its source—the academic lab—and systematically advance it to a commercially viable stage. This focus on strengthening a national innovation ecosystem from the ground up sets it apart. The direct integration between a public university's translational center and a commercial AI company creates a unique synergy that is difficult to replicate, providing a dedicated pipeline for novel biology that larger, more siloed organizations may overlook.

Leah Klapper, Managing Director of the BCDD, reinforced this mission-driven focus. "Our mission has always been to bridge the gap between outstanding academic science and real-world therapeutic innovation," she said. "By partnering with Evogene, and leveraging their cutting-edge ChemPass AI™ engine, we can provide researchers and entrepreneurs with a comprehensive drug discovery pipeline." The collaboration isn't just about providing a service; it's about building a platform to empower local scientists.

With this initiative, the partners are not just hoping to discover individual drugs but are building a sustainable engine for therapeutic innovation. The call to action is clear: researchers with deep biological insights, particularly those working on challenging targets like molecular glues and complex proteins, now have a clear and powerful pathway to translate their discoveries. By combining the creative spark of academic research with the analytical power of AI and the rigor of industrial validation, this collaboration may well become a blueprint for how other innovation hubs can turn their scientific brilliance into life-saving medicines.